Victory Capital Management Inc. Boosts Position in Cryolife Inc (NYSE:CRY)

Victory Capital Management Inc. lifted its stake in shares of Cryolife Inc (NYSE:CRY) by 7.1% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 17,913 shares of the medical equipment provider’s stock after acquiring an additional 1,184 shares during the period. Victory Capital Management Inc.’s holdings in Cryolife were worth $303,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of CRY. Lloyd Advisory Services LLC. acquired a new stake in shares of Cryolife during the 4th quarter worth about $27,000. Point72 Hong Kong Ltd acquired a new position in Cryolife in the 4th quarter valued at about $38,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Cryolife by 37.8% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,093 shares of the medical equipment provider’s stock valued at $52,000 after acquiring an additional 848 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Cryolife by 272.0% in the 1st quarter. PNC Financial Services Group Inc. now owns 4,564 shares of the medical equipment provider’s stock valued at $76,000 after acquiring an additional 3,337 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its position in Cryolife by 67.8% in the 1st quarter. Exchange Traded Concepts LLC now owns 5,375 shares of the medical equipment provider’s stock valued at $91,000 after acquiring an additional 2,171 shares in the last quarter. Institutional investors and hedge funds own 81.97% of the company’s stock.

CRY stock opened at $19.17 on Wednesday. The business has a 50 day moving average price of $22.01 and a 200 day moving average price of $23.85. The stock has a market cap of $682.35 million, a price-to-earnings ratio of -147.46 and a beta of 1.37. Cryolife Inc has a fifty-two week low of $12.63 and a fifty-two week high of $33.00. The company has a quick ratio of 3.66, a current ratio of 4.90 and a debt-to-equity ratio of 0.94.

Cryolife (NYSE:CRY) last posted its earnings results on Thursday, April 30th. The medical equipment provider reported ($0.08) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.10). The business had revenue of $66.43 million for the quarter, compared to analysts’ expectations of $66.11 million. Cryolife had a positive return on equity of 2.55% and a negative net margin of 1.69%. Cryolife’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.04 EPS. As a group, sell-side analysts anticipate that Cryolife Inc will post -0.17 EPS for the current year.

In other Cryolife news, Director Ronald D. Mccall sold 1,719 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $22.82, for a total value of $39,227.58. Following the completion of the sale, the director now owns 127,766 shares in the company, valued at $2,915,620.12. The sale was disclosed in a document filed with the SEC, which is available through this link. 4.70% of the stock is currently owned by insiders.

Several equities analysts have recently issued reports on the company. Lake Street Capital lifted their price objective on Cryolife from $22.00 to $27.00 and gave the company a “buy” rating in a research note on Friday, May 1st. Zacks Investment Research cut Cryolife from a “hold” rating to a “sell” rating in a research note on Monday, May 25th. ValuEngine upgraded Cryolife from a “hold” rating to a “buy” rating in a research note on Friday, March 20th. Needham & Company LLC assumed coverage on Cryolife in a research note on Tuesday. They issued a “buy” rating and a $29.00 price objective for the company. Finally, Oppenheimer decreased their price objective on Cryolife from $34.00 to $25.00 in a research note on Thursday, April 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $27.40.

About Cryolife

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Recommended Story: What is Compound Annual Growth Rate (CAGR)?

Institutional Ownership by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.